TRI Awarded Best Woman-Owned Business Enterprise CRO+ by GHP Magazine

TRI is the recipient of a 2016 International Life Sciences Award for Best Woman-Owned Business Enterprise (WBE) CRO+ by Global Health and Pharma (GHP). This merit-based award recognizes the innovation, dedication, and commitment shown by life science professionals and firms across the globe. Nora Lee, President and CEO, discusses the company and its innovative service offerings.

“Here at TRI we provide product development support services to the global drug, biologic, and medical device community through the effective combination of scientific, clinical, information technology, and communication services.

We have provided high quality services to clinical trial sponsors in the public and private sector for 36+ years. TRI’s success is based on the competence of our staff denoted by their qualifications and experience; and the high level of client satisfaction as evidenced by our number of repeat business.

We have developed new services and products that address pressing needs in the industry for predictive information and analytics. We offer next generation Risk-Based Monitoring support and cutting-edge Business Intelligence (BI) solutions to assist clients, sites, and partners in identifying, correcting, or avoiding problem areas within and across clinical programs.”

Working in such a competitive industry, Nora emphasizes the firm’s need to differentiate itself, and states that it does this by offering high quality services which cannot be found elsewhere on the market.

“We ensure we offer the very best service through an acute and active understanding of industry needs and challenges. Our knowledge combined with investments in talent and technology keep us at the forefront of the industry.

TRI’s strategy has been to organically grow at a measured pace to ensure that we offer our clients accessible staff, transparent procedures, and consistently high quality and reliable services, ensuring milestones are always met and expectations are often exceeded. At TRI, we understand that one size does not fit all, especially when it comes to clinical research projects. We are flexible and adapt our services and processes to best address each client’s needs.

As a final comment Nora makes it clear that the firm, part of a vibrant and innovative cluster, will continue to provide high quality services moving forward.

“TRI is part of the Greater Washington DC area cluster composed of 800+ life science companies as well as clinical research federal agencies, legislators, academic institutions, and service providers located in Maryland, Virginia, and Washington DC. Our dynamic cluster paves the way for innovation, contributes to the development of best practices, and attracts some of the best talent in the industry.”